-
FDA Approves Darzalex Faspro, Kyprolis, and Dexamethasone for Multiple Myeloma
AmericanPharmaceuticalReview
December 03, 2021
The FDA has approved daratumumab + hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) and carfilzomib (Kyprolis, Amgen, Inc.) plus dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior ...
-
NICE recommends Kyprolis triple combination treatment for multiple myeloma
pharmatimes
March 22, 2021
The National Institute for Health and Care Excellence (NICE) has recommended a triple combination therapy comprised of Amgen’s Kyprolis, lenalidomide and dexamethasone for the treatment of previously-treated multiple myeloma patients.
-
FDA Approves New Kyprolis, Darzalex Combination Regimen
americanpharmaceuticalreview
August 25, 2020
Amgen announced the U.S. Food and Drug Administration (FDA) has approved the expansion of the Kyprolis® (carfilzomib) U.S. prescribing information to include its use in combination with Darzalex® (daratumumab) plus dexamethasone (DKd) in two dosing ...
-
KYPROLIS, DARZALEX Combo Approved for Multiple Myeloma
contractpharma
August 24, 2020
The study's primary endpoint resulted in a 37% reduction in the risk of disease progression or death.
-
Amgen Submits Supplemental New Drug Application for Kyprolis
americanpharmaceuticalreview
August 28, 2018
Amgen announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to expand the Prescribing Information for Kyprolis (carfilzomib) to include a once-weekly dosing option in combination with dexamet